EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Treg-associated oligomannose N-glycans trigger immune dysregulation in myasthenia gravis

Pedro Carneiro, Manuel M Vicente, Inês Alves, Catarina M Azevedo, Íris Caramalho, Joana Gaifem, David Tente, Maria Isabel Leite, Ernestina Santos, Salomé S Pinho, Ângela Fernandes

Journal of Autoimmunity · 2026-12 · 165 · 103643

DOI: 10.1016/j.jaut.2026.103643 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Autoimmunity, 2026-12. Verfasst von Pedro Carneiro und 10 weiteren Autor:innen. Beteiligte Einrichtung: I3S - Institute for Research and Innovation in Health, University of Porto, Porto, 4200-135, Portugal; School of Medicine and Biomedical Sciences (IC…. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Lupus Research Alliance, European Crohn's & Colitis Organisation, Fundação Bial.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Myasthenia gravis (MG) is an autoimmune neurological disease driven by the production of autoantibodies against components of the neuromuscular junction, resulting in fatigable muscle weakness, and in more severe cases, leading to life-threatening complications. This breakdown of immune tolerance has been associated with an impaired suppressive function and altered frequency of Regulatory T cells (Tregs) in autoimmune diseases, including MG. As key regulators of immune tolerance, Tregs play a pivotal role in maintaining immune homeostasis through their ability to suppress other immune cells, controlling inflammation. Nevertheless, the mechanisms underlying Tregs dysfunction in MG pathogenesis are not fully understood. Here, we reveal the impact of Treg N-glycosylation on their immunoregulatory activity and function in the MG context. Glycan profiling by flow cytometry of circulating Tregs from MG patients (n = 72) and healthy controls (HCs; n = 24) revealed increased presence of oligomannose N-glycans in disease. Moreover, this specific Treg N-glycome profile was associated with disease severity, distinguishing between active disease and remission, being more pronounced in MG patients with additional autoimmune diseases, highlighting its potential as a disease biomarker. Functionally, in vitro abrogation of the N-glycosylation pathway in Tregs (mimicking the oligomannose enrichment found in the patients) resulted in impaired suppressive capacity over conventional T cells. Consistently, in the Experimental Autoimmune Myasthenia Gravis (EAMG) model, mice with altered Treg N-glycosylation exhibited worse clinical features and a reduced frequency of effector Tregs compared to wild-type controls. Altogether, these findings identify N-glycosylation as a mechanism underlying Treg dysfunction in MG, in which abnormal expression of mannose-enriched N-glycans in Tregs associates with compromised Treg suppressive function and increased disease severity, proposing Treg N-glycosylation as both a mechanistic driver of MG pathogenesis and a potential avenue for therapeutic intervention.

Schlagwörter

Stichwörter der Autor:innen

Myasthenia gravisN-GlycosylationRegulatory T cellsTherapeutic glycotarget

Autor:innen und Institutionen

  • I3S - Institute for Research and Innovation in Health, University of Porto, Porto, 4200-135, Portugal; School of Medicine and Biomedical Sciences (ICBAS), University of Porto, Porto, 4050-313, Portugal.
  • I3S - Institute for Research and Innovation in Health, University of Porto, Porto, 4200-135, Portugal; Institute of Clinical Biochemistry, Hannover Medical School, Hannover, 30625, Germany; NextGENERATION Medical Scient…
  • I3S - Institute for Research and Innovation in Health, University of Porto, Porto, 4200-135, Portugal.
  • BioISI - Institute of Biosystems and Integrative Sciences, Department of Chemistry and Biochemistry, Faculty of Sciences, University of Lisbon, Lisbon, 1749-016, Portugal.
  • CHUdSA - University Hospital Center of Santo António, Department of Neurology, Porto, 4050-342, Portugal.
  • Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, Oxford, OX3 9DU, UK.

Förderung

  • Lupus Research Alliance
  • European Crohn's & Colitis Organisation
  • Fundação Bial
  • Fundação para a Ciência e a Tecnologia
  • European Commission
  • European Society for Clinical Investigation
  • European Research Council
  • Else Kroner-Fresenius Foundation

Zitieren

APA

Carneiro, P., Vicente, M. M., Alves, I., Azevedo, C. M., Caramalho, Í., Gaifem, J., Tente, D., Leite, M. I., Santos, E., Pinho, S. S., & Fernandes, Â. (2026). Treg-associated oligomannose N-glycans trigger immune dysregulation in myasthenia gravis. Journal of Autoimmunity, 165, 103643. https://doi.org/10.1016/j.jaut.2026.103643

Vancouver

Carneiro P, Vicente MM, Alves I, Azevedo CM, Caramalho Í, Gaifem J, et al. Treg-associated oligomannose N-glycans trigger immune dysregulation in myasthenia gravis. Journal of Autoimmunity. 2026;165:103643. doi:10.1016/j.jaut.2026.103643

BibTeX
@article{Carneiro2026,
  author = {Carneiro, Pedro and Vicente, Manuel M and Alves, Inês and Azevedo, Catarina M and Caramalho, Íris and Gaifem, Joana and Tente, David and Leite, Maria Isabel and Santos, Ernestina and Pinho, Salomé S and Fernandes, Ângela},
  title = {Treg-associated oligomannose N-glycans trigger immune dysregulation in myasthenia gravis},
  journal = {Journal of Autoimmunity},
  year = {2026},
  volume = {165},
  pages = {103643},
  doi = {10.1016/j.jaut.2026.103643}
}
Kostenlos starten →